| Study ID | Studied Indication or Disease | Phase | Study Title | Synopsis |
|---|
| 20050242 | Type 2 diabetes | 1 | A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple, Oral Administration of AMG 221 in Overweight and Obese Subjects
|  |
| 20050243 | Type 2 diabetes | 1 | A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Inhibition of 11ß-HSD1 Activity Using the Ex Vivo Fat Biopsy Assay After Single or Multiple, Oral Administration of AMG 221 in Obese Subjects | |
| 20060143 | Type 2 diabetes | 1 | A Randomized, Open-Label, Single Dose Study to Determine Relative Oral Bioavailability of AMG 221 Administered as a Tablet Formulation vs Oral Suspension Formulation and to Evaluate Effect of Food on Bioavailability of Tablet Formulation in Overweight and Obese Subjects
| |
| 20060322 | Type 2 diabetes | 1b | A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Six Week Study to Evaluate the Safety and Pharmacodynamic Effects of AMG 221 in Subjects with Type 2 Diabetes | |
Amgen Worldwide